Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma that are in Phase II clinical trials. The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.…
The Board of Directors' resolution on the issuance of convertible loans
Pharma Equity Group (CPH: PEG) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 0.0748 DKK on 20 November 2026, down 36.9% over 52 weeks. Its 52-week range is 0.0602 DKK to 0.1200 DKK: the price is 37.7% below the high and 24.3% above the low.
Its market capitalisation is 91.82M DKK.
Pharma Equity Group reports return on equity of -99.6% and an operating margin of 0.0%.
Its debt exceeds its cash by 10.72M DKK, a debt-to-equity ratio of 0.32. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.